<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603599</url>
  </required_header>
  <id_info>
    <org_study_id>Merve L1CAM</org_study_id>
    <nct_id>NCT04603599</nct_id>
  </id_info>
  <brief_title>Relationship of Endometrial Cancer and Serum Soluble L1CAM Level</brief_title>
  <official_title>Relationship of Endometrial Cancer and Serum Soluble L1CAM Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of serum soluble L1CAM (sL1CAM) on the&#xD;
      diagnosis and prognosis of endometrial cancer. This prospective randomized controlled trial&#xD;
      will be conducted in patients who have undergone endometrial biopsy and whose pathology&#xD;
      results are reported as benign endometrial changes, endometrial hyperplasia, or endometrial&#xD;
      cancer. The sL1CAM level between groups will be compared. The relationship between prognostic&#xD;
      factors and serum sL1CAM will be evaluated in patients with endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum sL1CAM level</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">146</enrollment>
  <condition>Endometrium Cancer</condition>
  <arm_group>
    <arm_group_label>benign endometrial changes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>endometrial hyperplasia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>endometrial cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum soluble L1CAM (sL1CAM)</intervention_name>
    <description>blood sample</description>
    <arm_group_label>benign endometrial changes</arm_group_label>
    <arm_group_label>endometrial cancer</arm_group_label>
    <arm_group_label>endometrial hyperplasia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        benign endometrial changes, endometrial hyperplasia or endometrial cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent endometrial biopsy due to abnormal uterine bleeding and whose&#xD;
             pathology results were reported as benign endometrial changes, endometrial hyperplasia&#xD;
             or endometrial cancer were included in the study. All patients participating in the&#xD;
             study signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who did not have consent, received neoadjuvant therapy and who would not have&#xD;
             surgery despite endometrial cancer were excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Merve Demir</name>
      <address>
        <city>Kocaeli</city>
        <zip>41000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Merve Dermir</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

